JP6195609B2 - 治療剤として有用なスピロ−オキソインドール化合物の不斉合成 - Google Patents

治療剤として有用なスピロ−オキソインドール化合物の不斉合成 Download PDF

Info

Publication number
JP6195609B2
JP6195609B2 JP2015505723A JP2015505723A JP6195609B2 JP 6195609 B2 JP6195609 B2 JP 6195609B2 JP 2015505723 A JP2015505723 A JP 2015505723A JP 2015505723 A JP2015505723 A JP 2015505723A JP 6195609 B2 JP6195609 B2 JP 6195609B2
Authority
JP
Japan
Prior art keywords
formula
compound
pharmaceutically acceptable
acceptable salt
enantiomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015505723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516389A (ja
JP2015516389A5 (enExample
Inventor
シャオイ スン，
シャオイ スン，
ジャンミン フー，
ジャンミン フー，
サルタン チョウドリー，
サルタン チョウドリー，
アイバン ウィリアム ヘメオン，
アイバン ウィリアム ヘメオン，
マイケル エドワード グリムウッド，
マイケル エドワード グリムウッド，
タレク スハイル マンスール，
タレク スハイル マンスール，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of JP2015516389A publication Critical patent/JP2015516389A/ja
Publication of JP2015516389A5 publication Critical patent/JP2015516389A5/ja
Application granted granted Critical
Publication of JP6195609B2 publication Critical patent/JP6195609B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2015505723A 2012-04-12 2013-03-11 治療剤として有用なスピロ−オキソインドール化合物の不斉合成 Active JP6195609B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623336P 2012-04-12 2012-04-12
US61/623,336 2012-04-12
PCT/US2013/030219 WO2013154712A1 (en) 2012-04-12 2013-03-11 Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents

Publications (3)

Publication Number Publication Date
JP2015516389A JP2015516389A (ja) 2015-06-11
JP2015516389A5 JP2015516389A5 (enExample) 2016-04-07
JP6195609B2 true JP6195609B2 (ja) 2017-09-13

Family

ID=47902379

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015505723A Active JP6195609B2 (ja) 2012-04-12 2013-03-11 治療剤として有用なスピロ−オキソインドール化合物の不斉合成

Country Status (14)

Country Link
US (2) US9487535B2 (enExample)
EP (1) EP2838902B1 (enExample)
JP (1) JP6195609B2 (enExample)
KR (1) KR20150002794A (enExample)
CN (2) CN105753877A (enExample)
AU (1) AU2013246485A1 (enExample)
CA (1) CA2869547A1 (enExample)
EA (1) EA201491854A1 (enExample)
ES (1) ES2714314T3 (enExample)
HK (3) HK1205114A1 (enExample)
IL (1) IL235006A0 (enExample)
MX (1) MX2014012266A (enExample)
WO (1) WO2013154712A1 (enExample)
ZA (1) ZA201407334B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3032B1 (ar) 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
HK1205114A1 (en) 2012-04-12 2015-12-11 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2017180248A1 (en) * 2016-04-15 2017-10-19 William Marsh Rice University Enantioenriched viridicatumtoxin b analogs
WO2017214442A1 (en) 2016-06-08 2017-12-14 President And Fellows Of Harvard College Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome
JP2019518058A (ja) * 2016-06-16 2019-06-27 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． スピロ−オキシインドール化合物の固体状態形
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
CN108395438A (zh) * 2018-04-03 2018-08-14 陕西科技大学 一类具有抗菌活性的靛红母核螺环化合物及其合成方法
US12252457B2 (en) 2018-05-22 2025-03-18 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
EP3801512A4 (en) 2018-05-29 2022-01-19 President and Fellows of Harvard College COMPOSITIONS AND METHODS TO REDUCE TACTILE DYSFUNCTION, ANXIETY AND SOCIAL DISABILITIES
US12077512B2 (en) 2019-03-25 2024-09-03 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
US12552808B2 (en) 2020-09-03 2026-02-17 Amgen Inc. Diol desymmetrization by nucleophilic aromatic substitution

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723459A (en) 1971-04-23 1973-03-27 Mc Neil Labor Inc 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives
JPS6130554A (ja) 1984-07-23 1986-02-12 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤
DE3608088C2 (de) 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
IL87116A (en) 1987-07-17 1993-03-15 Schering Ag 9-halogen-(z)-prostaglandin derivatives and pharmaceutical compositions containing the same
US5314685A (en) 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
JP4044967B2 (ja) 1997-02-10 2008-02-06 小野薬品工業株式会社 １１，１５−ｏ−ジアルキルプロスタグランジンｅ誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
DE69821987T2 (de) 1997-12-25 2004-12-16 Ono Pharmaceutical Co. Ltd. Omega-cycloalkyl-prostaglandin e2 derivate
JP4087938B2 (ja) 1998-02-04 2008-05-21 高砂香料工業株式会社 ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物
US6235780B1 (en) 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
JPWO2005035498A1 (ja) 2003-10-08 2006-12-21 住友製薬株式会社 含窒素二環性化合物の摂食調節剤としての用途
BRPI0510719A (pt) 2004-05-05 2007-11-20 Unibioscreen Sa derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
CN101300012B (zh) 2005-09-01 2011-09-14 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物在制备治疗呼吸系统疾病的药物中的应用
WO2007081895A2 (en) * 2006-01-09 2007-07-19 Merck & Co., Inc. Preparation of substituted 2-hydroxygibba-1(10a), 2, 4, 4b-tetraen-6-ones
US20110294842A9 (en) 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
AU2007307635A1 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
WO2008046087A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro compounds and their uses as therapeutic agents
GB0704846D0 (en) 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
JO3032B1 (ar) 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
WO2010078307A1 (en) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
US8295257B2 (en) 2009-03-13 2012-10-23 Telcordia Technologies, Inc. Scalable disruptive-resistant communication method
WO2010132352A2 (en) * 2009-05-11 2010-11-18 Xenon Pharmaceuticals Inc. Spiro compounds and their use as therapeutic agents
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
US20110086899A1 (en) 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
HK1205114A1 (en) 2012-04-12 2015-12-11 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents

Also Published As

Publication number Publication date
AU2013246485A1 (en) 2014-10-16
US9487535B2 (en) 2016-11-08
EA201491854A1 (ru) 2015-03-31
HK1205113A1 (en) 2015-12-11
JP2015516389A (ja) 2015-06-11
HK1226389A1 (zh) 2017-09-29
EP2838902B1 (en) 2018-12-05
WO2013154712A1 (en) 2013-10-17
ES2714314T3 (es) 2019-05-28
CN105753877A (zh) 2016-07-13
CA2869547A1 (en) 2013-10-17
IL235006A0 (en) 2014-12-31
ZA201407334B (en) 2017-05-31
KR20150002794A (ko) 2015-01-07
EP2838902A1 (en) 2015-02-25
US20130274483A1 (en) 2013-10-17
US20170066777A1 (en) 2017-03-09
MX2014012266A (es) 2014-12-05
HK1205114A1 (en) 2015-12-11
CN104350057A (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
JP6195609B2 (ja) 治療剤として有用なスピロ−オキソインドール化合物の不斉合成
DE60222742T2 (de) Beta-lactam-verbindungen,herstellungsverfahren für diese verbindungen und serumhypocholesterinämiemittel, die diese verbindungen enthalten
DE69632916T2 (de) Substituierte Pyridinderivate, deren Herstellung und deren Verwendung als Modulatoren von Acetylcholin-Rezeptoren
AU650182B2 (en) Novel azaheterocyclylmethyl-chromans
TWI588136B (zh) 多環類衍生物、其製備方法及其在醫藥上的應用
EP2743261B1 (en) Preparation method of crystal form i of the racemate of 4-hydroxy-2-oxo-1-pyrrolidine-acetamide
AU2016213768B2 (en) Chemical process
JPH0544948B2 (enExample)
WO2017100546A1 (en) Methods for preparation of quinazoline derivatives
EP0507650B1 (fr) Dérivés de pipéridine, leur préparation et leur application en thérapeutique
CA2706566A1 (en) Chromane derivatives as trpv3 modulators
JP2879147B2 (ja) 新規な抗高血圧性ベンゾピラン誘導体
JP2010532357A (ja) １，２−置換３，４−ジオキソ−１−シクロブテン化合物における制御された結晶サイズのための方法
EP0402150A1 (en) New 2,5-diaryl tetrahydrofurans and analogs therof as PAF antagonists
CA2727669C (fr) Nouveaux derives de (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
Chandrasekhar et al. Practical and highly stereoselective approaches to the total synthesis of (−)-codonopsinine
CN115677507A (zh) 氟比洛芬衍生物及其在药物中的应用
DE602004009831T2 (de) Verfahren zur gewinnung von tolterodin
CN115836059B (zh) 异吲哚啉酮衍生物的制备方法、该方法所使用的新型中间体及其制备方法
CA1272214A (en) Spiro¬benzofuran-2(3h),1&#39;cycloheptane|s, a process and intermediates for their preparation and their use as medicaments
KR970011299B1 (ko) 고혈압 치료용 벤조피란 유도체
DE4032059A1 (de) Verfahren zur herstellung von optisch aktiven 4-aryl-2-pyrrolidinonen
Zhang et al. Supplementary Information for Nickel-Catalyzed Deaminative Sonogashira Coupling of Alkylpyridinium Salts Enabled by a New NN2 Pincer Ligand
DE3801479A1 (de) Pilocarpinderivate
DE4333189A1 (de) Adamantyl-imidazolyl-phenyl-methane und deren Salze, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170815

R150 Certificate of patent or registration of utility model

Ref document number: 6195609

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250